
![]() |
![]() |
|
Sopherion Therapeutics Inc. (now SPHN Holdings, Inc.) has leveraged its proprietary screening program to design and identify new therapies. The platform is built on a next generation peptide display technology called Minicell Peptide Display™ (MinPep Display or MPD) that is able to circumvent limitations inherent with conventional Phage or Bacterial display technologies. MPD uses minicells…small vesicles produced by bacteria that possess a critical mutation and lack chromosomal DNA. As a result, MPD has the following advantages:
Originally formed as an R&D company employing its proprietary technology platform for drug discovery, Sopherion has utilized its proprietary R&D platform to create a preclinical pipeline. Recently, Sopherion has decided to spin out or divest the R&D platform to a separate entity.
|
|||||
| Terms and Conditions |